27 February 2025
Latham & Watkins Advises on BridgeBio’s US$500 Million Convertible Senior Notes Offering
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Greg Rodgers Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Shayne Kennedy Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Ryan Gold | Latham & Watkins LLP | Associate | corporate | Not stated |
| Greg Van Buiten | Latham & Watkins LLP | Associate | corporate | Not stated |
| Andrew Bentz | Latham & Watkins LLP | Associate | corporate | Not stated |
| Steve Hess | Latham & Watkins LLP | Associate | corporate | Not stated |
| Elena Romanova | Latham & Watkins LLP | Partner | tax | Not stated |
| Aaron Bernstein | Latham & Watkins LLP | Partner | tax | Not stated |
| Kirt Switzer | Latham & Watkins LLP | Partner | tax | Not stated |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 500m (US$500 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- BridgeBio Pharma, Inc. (Issuer)